Table 1

Inclusion criteria

Eligible patients must meet all of the following criteria to be included in the OVHIPEC-2 trial:
1.signed and written informed consent
2.age ≥18
3.histological proven FIGO stage III primary epithelial ovarian, fallopian tube, or extra-ovarian cancer, treated with primary complete cytoreduction, or primary cytoreduction with no more than 2.5 mm residual disease
a. in case of extra-abdominal enlarged lymph nodes, representative cytology/histology or FDG-PET scan must be negative;
b. resectable, local bowel involvement, or spleen, or umbilical lesions are allowed;
c. in case no histological proof is available before surgery, patients can be randomized during surgery based on histological proof on intraoperative frozen section material for major surgery, WHO performance status 0–2
5.adequate bone marrow function
(hemoglobin level >5.5 mmol/L; neutrophils>1.5×109/L; platelets>100×109/L)
6.adequate hepatic function (ALT, AST, and bilirubin <2.5 times upper limit of normal)
a. in case of Gilbert’s disease: bilirubin <5 times upper limit of normal
7.adequate renal function (creatinine clearance using Cockcroft-Gault formula ≥60 mL/min)
8.baseline health-outcome questionnaire should be completed before randomization to understand the patient information and questionnaires